Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649203 | 0.95 | HDAC4 (0.45) | HDAC4GPR119SLC6A4HDAC6USP30 | |
| SCHEMBL647519 | 0.92 | GPR119 (0.43) | HDAC4GPR119HRH3PARP1CA12 | |
| SCHEMBL4449340 | 0.91 | GPR119 (0.44) | HDAC4GPR119USP30HRH3PARP1 | |
| SCHEMBL4408236 | 0.91 | GPR119 (0.52) | GPR119HRH3PARP1LMNAMAPT | |
| SCHEMBL649869 | 0.90 | HDAC4 (0.46) | HDAC4GPR119SLC6A4HDAC6USP30 | |
| SCHEMBL649433 | 0.90 | HDAC4 (0.46) | HDAC4GPR119SLC6A4HDAC6USP30 | |
| SCHEMBL2504574 | 0.87 | HDAC4 (0.46) | HDAC4GPR119HDAC6HRH3PARP1 | |
| SCHEMBL648854 | 0.86 | PRKAA2 (0.44) | SLC6A4MAPT | |
| SCHEMBL4405719 | 0.86 | GPR119 (0.52) | GPR119HRH3PARP1LMNAMAPT | |
| SCHEMBL62615 | 0.86 | HDAC4 (0.51) | HDAC4GPR119HDAC6HRH3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231600-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | claimed |
| WO-2009065131-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | claimed |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-06-26 | — | — | US | disclosed |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2024-12-10 | — | — | US | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| WO-2024146619-A1 | AURONE DERIVATIVE OR ANALOG, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 中国科学院上海药物研究所 | 2024-07-11 | — | — | WO | disclosed |
| CN-118307504-A | Orange ketone derivative or analogue, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-07-09 | — | — | CN | disclosed |
| US-12006301-B1 | And synthesis of dual 5-HT1A and 5-HT7 receptor ligands | FLORIDA A&M UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| CN-115677635-B | Orange ketone derivative and application thereof | 中国科学院新疆理化技术研究所 | 2024-04-09 | — | — | CN | disclosed |
| WO-2024019957-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CELGENE CORPORATION (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20070088004-A1 | Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); | JENRIN DISCOVERY, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20070088004-A1 | Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); | JENRIN DISCOVERY, INC. | 2007-04-19 | — | — | US | disclosed |
| US-20070072926-A1 | Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases | ALLERGAN, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072926-A1 | Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases | ALLERGAN, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2007001249-A1 | NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES | PHARMACOPEIA, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2006008316-A2 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHESES | Universität des Saarlandes (DE) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006002763-A2 | SUBSTITUTED TETRAHYDROISOCHINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRAGS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-01-12 | — | — | WO | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | PHARMACOPEIA, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222203-A1 | [4(2-methylamino-3-methyl)benzimidazol]1-[(4-carboxyethylamido-2,5-dimethyloxy)phenyl]ester; vitronectin receptor antagonist; endometriosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity; disruption of osteoclast adhesion | MSR1, EDNRA, GPR174 | HDAC4 1217/4885GPR119 9/4885SLC6A4 3784/4885 |
| US-20070088004-A1 | Monoamine oxidase-B inhibitors; , and/or cardiometabolic disorders ( hypertension, dyslipidemias, high blood pressure, and insulin resistance); | MAOB, MAOA, APOB | HDAC4 750/4885GPR119 4/4885SLC6A4 208/4885 |
| US-12006301-B1 | And synthesis of dual 5-HT1A and 5-HT7 receptor ligands | HTR7, HTR1A, HTR5A | HDAC4 4145/4885GPR119 440/4885SLC6A4 22/4885 |
| US-20070072926-A1 | Dextrorotatory and levo-rotatory enantiomers; specific to alpha2B adrenergic receptors; chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain and other diseases | ADRA2A, ADRA2B, ADRB2 | HDAC4 3959/4885GPR119 132/4885SLC6A4 642/4885 |
| US-20090170829-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | HDAC4 550/4885GPR119 15/4885SLC6A4 2178/4885 |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | AADAC, ENPP2, ATXN10 | HDAC4 44/4885GPR119 1504/4885SLC6A4 2810/4885 |
| US-20250205204-A1 | Transcription Factor Brn2 Inhibitory Compounds for Use as Therapeutics | BRDT, BRPF3, BRIX1 | HDAC4 318/4885GPR119 1559/4885SLC6A4 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.